Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer

Drugs

Volumn 35, Issue 6, 1988, Pages 685-710

  Lonning P E ^a   Kvinnsland, S ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE; CORTICOTROPIN; ESTROGEN;

AGE; ANIMAL EXPERIMENT; BREAST CANCER; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MENOPAUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; REVIEW;

AMINOGLUTETHIMIDE; BREAST NEOPLASMS; FEMALE; HUMAN; MALE; SUPPORT, NON-U.S. GOV'T;

EID: 0023726485     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198835060-00005     Document Type: Review

References (214)

1. Comparative studies on aromatase inhibitors in relation to the significance of estrogen synthesis in human mammary tumors
2. High-performance liquid Chromatographic assay for simultaneous estimation of aminoglutethimide and acetylaminoglutethimide in biological fluids
3. The effect of acetylator phenotype on the disposition of aminoglutethimide
4. Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone
5. A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone
6. Treatment of metastatic breast cancer with aminoglutethimide
7. Metabolism of aminoglutethimide in humans: formation of N-formylaminoglutethimide and nitroglutethimide
8. 1-testolactone
9. Effects of prolactin and luteinizing hormone on the cholesterol stores in the mouse testis
10. Evidence of the direct aromatization of testosterone and different aromatization sites for testosterone and androstenedione in human placental microsomes
11. The use of aminoglutethimide for the treatment of advanced breast cancer: correlations with prior treatment, ER and menstrual status
12. Evaluation of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumours refractory to hormonal therapy
13. Metabolism of estrogens — natural and synthetic
14. Effect of rifampicin treatment on the metabolism of ocstradiol and 17-alpha-cthinylocstradiol by human liver microsomes
15. Aminoglutcthimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500mg and Ig per day
16. A reassessment of the role of breast tumor aromatization
17. Enzymes of estrogen metabolism
18. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma
19. Aminoglutcthimide as second-line endocrine therapy in advanced breast cancer
20. Influence of ACTH on aminoglutethimide-induccd reduction of plasma steroids in postmenopausal breast cancer
21. Pros and cons of aminoglutcthimidc for advanced postmcnopausal breast cancer
22. Phenobarbital-induced increase in 6β-hydroxycortisol excretion: clue to its significance in human urine
23. Hematologie adverse effects of aminoglutcthimidc
24. Aminoglutethimidc after tamoxifen therapy in advanced breast cancer: M.D. Anderson Hospital experience
25. Inhibition of adrenal stcroidogenesis by aminoglutethimide and the mechanism of action
26. Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal stcroidogencsis: mechanism of action and therapeutic trial
27. Ovarian dysfunction associated with an anticonvulsant drug
28. Drug control of Cushing’s syndrome
29. Aminoglutethimide inhibition of adrenal desmolase activity
30. Increased activity of androgen hydroxylases in liver microsomes of rats pretreatcd with phenobarbital and other drugs
31. Effects of drugs and environmental chemicals on steroid metabolism
32. Decreased hypnotic action of progesterone and other steroids in rats pretreated with drugs that stimulate steroid metabolism
33. Polymorphically acctylated aminoglutcthimide in humans
34. 4-Hydroxy-androstenedione in treatment of postmenopausal patients with advanced breast cancer
35. Effect of phenobarbital and glutethimide on biological half-life of warfarin
36. Intracellular movement of cholesterol in rat adrenal cells: kinetics and effects of inhibitors
37. Aminoglutethimide as an inducer of oxidative drug metabolism in the rat
38. Bilateral adrenalectomy in the treatment of cancer of the breast
39. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action
40. The urinary excretion of aminoglutethimide in man
41. The partial fate of aminoglutcthimidc in man
42. A comparison of the endocrine effects of low-dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients
43. Effective inhibition by low-dose aminoglucthimide of peripheral aromatization in postmcnopausal breast cancer patients
44. Endogenous ocstradiol-17β concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content
45. Changes in cortisol metabolism following rifampicin therapy
46. Aminoglutethimide as second-line therapy in advanced breast cancer
47. Aminoglutethimide inhibits steroidogenesis in the rat testis
48. Absorption and elimination of aminoglutethimide in the rat and guinea pig. IRCS Medical Science
49. Pathway and stereochemistry of the formation of estriols in man
50. Estrone and estradiol content in human breast tumours: relationship to estradiol receptors
51. Effects of aminoglutethimide on adrenal function in man
52. Control of ovarian cholesterol ester biosynthesis
53. Aromatization of androstenedione to estrone by human adipose tissue invitro: correlation with adipose tissue mass, age and endometrial neoplasia
54. Metabolism of aminoglutethimide in humans: identification of four new urinary metabolites
55. The results of adrenalectomy in advanced breast cancer in 500 consecutive patients. Surgery
56. Human fatty marrow aromatizes androgen to estrogen
57. Treatment of advanced breast cancer with aminoglutethimide: a 14-year experience
58. Pharmacologie alteration of steroid hormone functions
59. Cholestatic jaundice and aminoglutethimide
60. Aminoglutethimide-induced leucopenia: a case report and review of the literature
61. Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism
62. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrestenedione: phase II report
63. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide
64. Preliminary trial of aminoglutethimide in breast cancer
65. Source of estrogen production in postmenopausal woman
66. In vivometabolism of progestins. iV. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyproges-terone acetate in women
67. Treatment of metastatic breast cancer with aminoglutethimide
68. Low-dose aminoglutethimide (125mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer
69. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer
70. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer
71. Role of aminoglutethimide in male breast cancer
72. 2α by aminoglutethimide in advanced breast cancer
73. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer
74. Crossover comparison of tamoxifen and aminoglutethimide in advanced breast cancer
75. Assessment of response to therapy in advanced breast cancer
76. A study of estrogen metabolic clearance rates and transfer factors
77. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patient with advanced breast cancer
78. 1), einem neuen Inhibitor der Steroidbiosynthese in der Nebenniere
79. Effect of aminoglutethimide on urinary steroid excretion in patients with congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency
80. Effect of aminoglutethimide on extraglandular metabolism of exogenous testosterone
81. Aminoglutethimide: a ‘side effect’ turned to therapeutic advantage
82. Steroidbiosynthesis by zona fusciculata and zona reticularis cells purified from the mammalian adrenal cortex
83. Nonadrenal female pseudohermaphroditism: an unusual case of fetal masculinization
84. Factors influencing estrogen production and metabolism in postmenopausal women with endocrine cancer
85. Metabolism of aminoglutethimide in humans: identification of hydroxylaminoglutethimide as an induced metabolite
86. Inhibition of adrenal steroidogenesis by glutethimide
87. Origin of serum estradiol in postmenopausal women
88. Über die Adrenale Steroid-Biosynthese in vitro III. Selektive Hemmung der Nebennierenrinden-Funktion
89. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer
90. Androgen-estrogen production rates in potmenopausal women with breast cancer
91. Irreversible thrombocytopenia following aminoglutethimide
92. Adrenal cells in tissue culture. IV. Use of an inhibitor of steroid synthesis for the study of ACTH action
93. Similarities between oxidative drug-metabolizing enzymes and steroid hydroxylases in liver microsomes
94. Treatment of breast carcinoma with aminoglutethimide
95. Effect of phenobarbital on theophylline disposition
96. Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy
97. Pancytopenia induced by aminoglutethimide in the treatment of breast cancer
98. Inhibition of steroidogenesis at various sites in the biosynthetic pathway in relation to induced ovulation
99. Randomized trial of aminoglutethimide v ersustamoxifen in metastatic breast cancer
100. Treatment of advanced prostate cancer with aminoglutethimide. 2nd European Conference on Clinical Oncology, Amsterdam, November 1983. Abstract no 13-09, p. 152. Longcope C. The metabolism of estrone sulfate in normal males
101. Metabolic clearance rates and interconversions of estrone and 17β-estradiol in normal males and females
102. 3H-estrone
103. Effect of aminoglutethimide on antipyrinc. thcophylline and digitoxin disposition in breast cancer
104. Aminoglutethimide and warfarin: a new important drug interaction
105. Single-dose and steady-state pharmacokinctics of aminoglutcthimidc
106. The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer
107. The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypoprothrom-binemic responses in man
108. A dissociated effect of aminoglutethimide on the mineralocorticoid secretion in man
109. Aminoglutethimide and advanced breast cancer
110. Aromatization by skeletal muscle
111. Systemic lupus crythematosus induced by aminoglutethimide
112. Testicular activity in Cushing’s disease
113. Effects of aminoglutethimidc in a case of cctopic ACTH syndrome
114. 3H-estradiol by normal breast and breast tumour tissues in postmenopausal women
115. Regulation of aromatase activity of stromal cells derived from human adipose tissue
116. Determination of aminoglutethimide and N-acctyl-aminoglutethimide in human plasma by high performance liquid chromatography
117. Steroid metabolism in breast cancer
118. Endogenous steroid concentration in human breast tumours determined by high-resolution mass fragmentography
119. Serum aminoglutcthimidc levels: studies of serum half-life, clearance, and patient compliance
120. Aminoglutcthimidc in tamoxifen-rcsistant patients: the Melbourne experience
121. Low-dose aminoglutcthimidc without steroid replacement in the treatment of postmcnopausal women with advanced breast cancer
122. Treatment of advanced prostatic cancer, resistant to conventional therapy, with aminoglutethimide
123. Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer
124. Medical and surgical adrenalcctomy in patients with advanced breast carcinoma
125. Medical adrenalcctomy and plasma steroids in advanced breast carcinoma
126. Aminoglutcthimidc: absorption, physiological disposition and pharmacokinctics
127. Aromatization of androgens by human abdominal and breast fat tissue
128. Wirkung von Rifampicin auf den Menstruationsyzyklus und die Østrogenausscheidung bei Einnahme oraler Kontrazcptiva
129. Interaction between estrogen and dilantin in a menopausal woman
130. Die Wirkung von Aminoglutethimid auf die Zwischcnzellcn des Rattenhodens. Virchows Archiv. A
131. Clinical pharmacokinctics of thcophyllinc
132. Measurement of urinary 6-β-hydroxycortisol excretion as an invivoparameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrinc phenobarbitone and rifampicin
133. Interaction of sodium warfarin and rifampicin: studies in man
134. Multiple forms of aromatasc and response of breast cancer aromatasc to antiplaccntal aromatasc II antibodies
135. Estrogen receptor status and the clinical response to a combination of aminoglutethimide and cortisol in advanced breast cancer
136. A 60.000 molecular weight human pituitary glycopeptide stimulates adrenal androgen secretion
137. Metastatic breast cancer in males
138. The interconversion and aromatization of androgens by human adipose tissue
139. Aminoglutethimide and cholestasis
140. Einfluss von Tuberkulostatika auf die Pharmakokinetik des Digitoxins
141. Effect of phenobarbital on the disposition of intravenous thcophyllinc
142. Antithyroid and antiadrenocortical activity of aminoglutethimide
143. Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer
144. Androgen production and conversion to estrogens in normal postmcnopausal women and in selected breast cancer patients
145. Clinical trial of multiple endocrine therapy for mctastatic and locally advanced breast cancer with tamoxifcn-aminoglutcthimidc-danazol compared to tamoxifen used alone
146. Aminoglutcthimide as second-line endocrine treatment in mctastatic breast cancer
147. Mitochondrial cavitation and hypertrophy in rat adrenal cortex due to aminoglutethimide
148. Plasma estrogens in postmcnopausal women
149. Goitrous hypothyroidism induced by aminoglutethimide. anticonvulsant drug
150. Estrogen production and metabolism in normal postmcnopausal women and postmcnopausal women with breast or endometrial cancer
151. Liquid-chromatographic determination of aminoglutcthimide in plasma
152. Adrenal suppression in the treatment of carcinoma of the prostate
153. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma
154. Postmcnopausal oestrogen production and its inhibition
155. Estrone-sulfate: production rate and metabolism in man
156. Basic studies on aminoglutethimide
157. 5- steroids in postmcnopausal women treated for breast carcinoma
158. Potency of the effect of D-stcrcoisomcr of aminoglutethimide on adrenal and extra-adrenal steroidogencsis
159. Plasma estronc-sulfatc assessment of reduced estrogen production during treatment of mctastatic breast carcinoma
160. Preservation of androgen secretion during estrogen suppression with aminoglutcthimidc in the treatment of metastatic breast carcinoma
161. Aminoglutcthimidc medical adrenalectomy for advanced prostatic carcinoma
162. Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalcctomy) as treatment of advanced breast carcinoma: a review
163. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives
164. Acute effects of aminoglutcthimide on testicular sleroidogcnesis in normal men
165. Successful medical adrenalectomy with aminoglutethimide: role of altered drug metabolism
166. Medical adrenalcctomy for metastatic breast carcinoma
167. Adrenal of male dog secretes androgens and estrogens
168. Resistance of the ovary to blockade of aromatization with aminoglutethimidc
169. Aminoglutcthimide inhibits extraglandular estrogen production in postmcnopausal women with breast carcinoma
170. In v ivoand in v itropharmacological studies of aminoglutethimide as an aromatase inhibitor
171. Compensatory increase in TSH secretion without effect on prolactin secretion in patients treated with aminoglutethimide
172. Adrenal suppression with aminoglutethimidc I. Differential effects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisonc
173. Aminoglutethimide as treatment of postmcnopausal women with advanced breast carcinoma
174. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer
175. In s ituestrogen production via the estrone sulfatase pathway in breast tumours: relative importance versusthe aromatase pathway
176. Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by rcvcrscd-phase liquid chromatography
177. Aminoglutethimide and metastatic adrenal cancer
178. Effects of aminoglutcthimide upon adrenal function and cortisol metabolism in Cushing’s syndrome
179. Aromatization of androstenedione by isolated human hairs
180. Aromatization of androstencdione by cultured human fibroblasts
181. The influence of NADPH or its generating system on corticosteroid biosynthesis by rat adrenal homogenatcs
182. Estrogen formation in stromal cells of adipose tissue of women: induction by glucocorticosteroids
183. Tamoxifen versusaminoglutethimide in advanced breast carcinoma: a randomized crossover trial
184. Aromatization of androstenedione by human adult liver in vitro
185. Induetion of the metabolism of digitoxin in man by phenobarbital
186. Effect of N-phcnylbarbital (Phetharbital) on the metabolism of testosterone and cortisol in man
187. The effect of aminoglutethimidc on the metabolism of testosterone in rat liver invitro
188. Failure of aminoglutethimide to produce changes in morphology and steroid biosynthesis of rat testicles
189. Observations on the pharmacokinetics of low-dose aminoglutethimide in patients with advanced breast cancer
190. Low dose aminoglutethimide in treatment of breast cancer
191. Endocrine effects of low-dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer
192. Goiters with high radioactive uptake and other characteristics of iodine deficiency in rats chronically treated with aminoglutethimide
193. The involvement of human placental microsomal cytochrome p-450 in aromatization
194. Aminoglutethimide bioavailability, pharmacokinetics, and binding to blood constituents
195. Biological significance of aromatase activity in human breast tumors
196. Aminoglutethimide and glutethimide: effects on 18-hydroxy-corticosterone biosynthesis by human and sheep adrenals in vitro
197. Differential induction of antipyrine metabolism by rifampicin
198. Aminoglutethimide in the treatment of metastatic breast cancer
199. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol
200. The hormonal activity of the postmenopausal ovary
201. Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women
202. Effects of aminoglutethimide on adrenal steroid secretion
203. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man
204. Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer
205. A dose response evaluation of delta-1-testololactone in advanced breast cancer
206. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer
207. Verstarkte Hydroxylierung von Østrogenen beim Menschen nach Arzneimittelgabe Nachweis durch HTO-Analysis des Kørperwassers
208. Commentary: a physiological approach to hepatic drug clearance
209. Pharmacokinetic interactions with rifampicin